肝宝颗粒辅助易善复治疗非酒精性脂肪肝临床疗效观察
Clinical Observation of Traditional Chinese Medicine Preparation-Ganbao Particulate Adjuvant Treatment of Young and Middle-Aged Men with Non-Alcoholic Fatty Liver

作者: 季洪赞 , 吴 琳 , 吴晓尉 , 李海兵 , 戎建明 , 施 慧 , 许莲娥 , 刘 炯 , 汪芳裕 :南京军区南京总医院消化内科,江苏 南京;

关键词: 肝宝颗粒多烯磷脂酰胆碱非酒精性脂肪肝The Particles of Ganbao Polyene Phosphatidylcholine Non-Alcoholic Fatty Liver

摘要:
目的:对比观察中药制剂肝宝颗粒联合易善复(多烯磷脂酰胆碱)与单剂易善复治疗非酒精性脂肪肝的临床效果。方法:选取肝功能异常的符合非酒精性脂肪肝诊断的患者152例,随机分成每组152例,观察治疗组和对照治疗组各38例,观察组使用肝宝颗粒与易善复,对照组单剂使用易善复,年龄:观察治疗组与对照治疗组,分别为19岁~52岁(31.61 ± 8.52)和17岁~51岁(30.53 ± 10.15),两组患者均符合2010年非酒精性脂肪性肝病诊疗指南诊断标准, 且对治疗方案知情同意。观察两组患者的肝功能(TBIL、DBIL、ALT、AST)和内毒素、血脂、糖化血红蛋白、胰岛β细胞功能(FINS/FBG)等指标的变化。结果:观察组肝功能总有效率为97.37%(144/152)高于对照组的78.95%(120/152),具有统计学意义(p < 0.01),观察组的显效率为47.37%(72/152),好于对照组的肝功能显效率23.68%(36/152) (p > 0.05),治疗组的胰岛β细胞功能提高好于对照组(p < 0.01)。结论:肝宝颗粒联合多烯磷脂酰胆碱对脂肪肝的治疗既有较好的疗效,又对胰岛β细胞功能产生较好的作用。

Abstract: Objective: To compare and observe the clinical effect of the traditional Chinese medicine Ganbao particles combined with Essentiale (polyene phosphatidyl choline) with the clinical effect of single agent Essentiale to treat the non-alcoholic fatty liver. Method: Clinical cases of 152 cases of liver function damage were collected. All of them were in accordance with the diagnostic criteria of non-alcoholic fatty liver disease, and were randomly divided into two groups. The observation group was treated with Ganbao granule and Essentiale capsules. The control group was treated with a single oral Essentiale capsules. Age: the age range of the observation group was 19 to 52 years old (31.61 + 8.52). The age range of the control group was 17 to 51 years old (30.53 + 10.15). Patients in the two groups were all informed about the treatment plan and signed a consent form. Experimental detection indicators of the two groups included TBIL, DBIL, ALT, AST, endotoxin, blood lipids, glycosylated hemoglobin and islet beta cell function (FINS/FBG) and other clinical in-dicators. Results: In the observation group, the total effective rate was 97.37% (144/152), which was significantly higher than that in the control group (120/152), which was statistically significant (P < 0.01). The therapeutic effect of observation group was 47.37% (72/152), which was sig-nificantly higher than that of control group whose treatment effect was 23.68% (36/152) (P > 0.05). The protective improvement of islet beta cell function in the observation group was higher than that in the control group (P < 0.01). Conclusion: The treatment of the combination of Ganbao particles and the polyene phosphatidylcholine not only has a positive effect on the NFLD but also can improve the function of the pancreatic β cell.

文章引用: 季洪赞 , 吴 琳 , 吴晓尉 , 李海兵 , 戎建明 , 施 慧 , 许莲娥 , 刘 炯 , 汪芳裕 (2016) 肝宝颗粒辅助易善复治疗非酒精性脂肪肝临床疗效观察。 临床医学进展, 6, 1-7. doi: 10.12677/ACM.2016.61001

参考文献

[1] 丁雯瑾, 范建高. 世界胃肠病组织非酒精性脂肪性肝病诊疗指南简介[J]. 实用肝脏病杂志, 2014, 17(5): I-V..

[2] 范建高, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版) [J]. 胃肠病学和肝病学杂志, 2010, 19(6): 483-487.

[3] 季洪赞, 龚维忠, 杨继红, 等. 老年人糖耐量低减的冠心病与β细胞功能及脂代谢的关系[J]. 心脏杂志, 2001, 13(6): 448-452.

[4] 王魁彬.中西医结合治疗非酒精性脂肪肝的临床观察[J]. 中国现代药物应用, 2015, 9(16): 150-151.

[5] 施军平, 范建高. 2011年非酒精性脂肪性肝病治疗进展[J]. 实用肝脏病杂志, 2012 , 15(2): 84-86.

[6] Zheng, W., Mclerran, D.F., Rolland, B., et al. (2011) Association between Body-Mass Index and Risk of Death in More than 1 Million Asians. The New England Journal of Medicine, 364, 719-729.
http://dx.doi.org/10.1056/NEJMoa1010679

[7] Wu, J.Y., Duan, X.Y., Li, L., et al. (2010) Dyslipidemia in Shanghai, China. Preventive Medicine, 51, 412-415.
http://dx.doi.org/10.1016/j.ypmed.2010.08.013

[8] Yang, W., Lu, J., Weng, J., et al. (2010) Prevalence of Di-abetes among Men and Women in China. The New England Journal of Medicine, 362, 1090-1101.
http://dx.doi.org/10.1056/NEJMoa0908292

[9] 孙健, 周春蕾, 刘红梅. 中西医结合治疗脂肪肝的临床研究[J]. 中外医疗, 2011, 30(16): 29-30.

[10] Murphy, P., Hooker, J., Ang, B., et al. (2015) Associations between Histo-logic Features of Nonalcoholic Fatty Liver Disease (NAFLD) and Quantitative Diffusion-Weighted MRI Measurements in Adults. Journal of Magnetic Resonance Imaging, 41, 1629-1638.
http://dx.doi.org/10.1002/jmri.24755

[11] Fan, J.G., Saibara, T., Chitturi, S., et al. (2007) What Are the Risk Factors and Settings of Nonalcoholic Fatty Liver Disease in Asia-Pacific. Journal of Gastroenterology and Hepatology, 22, 794-800.
http://dx.doi.org/10.1111/j.1440-1746.2007.04952.x

[12] Marciniak, B., Kimber-Trojnar, Z., Leszczyns-ka-Gorzelak, B., et al. (2011) Treatment of Obstetric Cholestasis with Polyunsaturated Phosphatidylcholine and Urso-deoxycholic Acid. Ginekologia Polska, 82, 26-31.

[13] Pettinelli, P., Obregon, A.M., Videla, L.A., et al. (2011) Mo-lecular Mechanisms of Steatosis in Nonalcoholic Fatty Liver Disease. Nutrición Hospitalaria, 26, 441-450.

[14] Shapiro, H., Tehilla, M., Attal-Singer, J., et al. (2011) The Therapeutic Potential of Long-Chain Omega-3 Fatty Acids in Nonalcoholic Fatty Liver Disease. Clinical Nutrition, 30, 6-19.
http://dx.doi.org/10.1016/j.clnu.2010.06.001

[15] Mouzaki, M. and Allard, J.P. (2012) The Role of Nutrients in the Development, Progression, and Treatment of Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 46, 457-467.
http://dx.doi.org/10.1097/MCG.0b013e31824cf51e

[16] Kim, M.S., Kung, S., Grewal, T., et al. (2012) Possible Molecular Mechanisms Soy-Mediated in Preventing and Treating Nonalcoholic Fatty Liver Disease. Nutrición Hospi-talaria, 27, 991-998.

[17] 王灵台. 中西医结合治疗非酒精性脂肪肝现状的思考[J]. 中国中西医结合杂志, 2009, 29(12): 1061-1063.

[18] Shi, K.Q., Fan, Y.C., Liu, W.Y., et al. (2012) Traditional Chinese Medicines Benefit to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Molecular Biology Reports, 39, 9715-9722.
http://dx.doi.org/10.1007/s11033-012-1836-0

[19] Dong, H., Lu, F.E. and Zhao, L. (2012) Chinese Herbal Medi-cine in the Treatment of Nonalcoholic Fatty Liver Disease. Chinese Journal of Integrative Medicine, 18, 152-160.
http://dx.doi.org/10.1007/s11655-012-0993-2

[20] Sheng, X., Wang, M., Lu, M., et al. (2011) Rhein Ameliorates Fatty Liver Disease through Negative Energy Balance, Hepatic Lipogenic Regulation, and Immunomodulation in Di-et-Induced Obese Mice. American Journal of Physiology—Endocrinology and Metabolism, 300, E886-E893.
http://dx.doi.org/10.1152/ajpendo.00332.2010

[21] 肖本富. 中西医结合治疗脂肪肝的临床疗效观察[J]. 中国保健营养, 2012(12): 179-181.

[22] Schrieber, S.J., Hawke, R.L., Wen, Z., et al. (2011) Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C. Drug Metabolism and Disposition, 39, 2182-2190.
http://dx.doi.org/10.1124/dmd.111.040212

[23] Lee, J.T., Pao, L.H., Lee, M.S., et al. (2013) A New Approach to Facilitate Diagnosis of Nonalcoholic Fatty Liver Disease through a Galactose Single Point Method in Rats with Fatty Liver. Digestive and Liver Disease, 45, 134-141.
http://dx.doi.org/10.1016/j.dld.2012.08.019

[24] Harte, A.L., da Silva, N.F., Creely, S.J., et al. (2010) Elevated Endotoxin Levels in Non-Alcoholic Fatty Liver Disease. Journal of Inflammation, 7, 15.
http://dx.doi.org/10.1186/1476-9255-7-15

[25] Liu, Y., Han, X., Bian, Z., et al. (2012) Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 57, 390-398.
http://dx.doi.org/10.1007/s10620-011-1902-9

[26] Thuy, S., Ladurner, R., Volynets, V., et al. (2008) Nonalcoholic Fatty Liver Disease in Humans Is Associated with Increased Plasma Endotoxin and Plasminogen Activator Inhibitor 1 Concentrations and with Fructose Intake. Journal of Nutrition, 138, 1452-1455.

[27] Spruss, A., Henkel, J., Kanuri, G., et al. (2012) Female Mice Are More Susceptible to Nonalcoholic Fatty Liver Disease: Sex-Specific Regulation of the Hepatic AMP-Activated Protein Kinase-Plasminogen Activator Inhibitor 1 Cascade, but Not the Hepatic Endotoxin Response. Molecular Medicine, 18, 1346-1355.
http://dx.doi.org/10.2119/molmed.2012.00223

分享
Top